Licensed Vocational Nurse in Montana Medicare Details, Address, Contact
3 Licensed Vocational Nurse nurses found. Showing 1 - 3
 Stacy Tan, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 535 Clinic Rd E, Box Elder, MT 59521 Phone: 406-395-4395 |
Gina Lee Mago, Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 3687 Veterans Dr, Fort Harrison, MT 59636 Phone: 406-447-7182 |
Kim Marie Edelbach, LPN Licensed Vocational Nurse Medicare: Not Enrolled in Medicare Practice Location: 209 N 10th St Ste A, Hamilton, MT 59840 Phone: 406-532-9101 Fax: 406-363-4498 |
News Archive
Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution
Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.
Authorities in India's only Muslim-majority state battling increase in female foeticide, AFP reports
Agence France-Presse examines how officials in the Indian state of Jammu and Kashmir are battling a "shocking rise in female foeticide" by seizing unlicensed ultrasound machines and enlisting the assistance of religious leaders in the country's only Muslim-majority state.
MDs' reactions to pharma marketing influenced by brand, side effects
A study of pharmaceutical companies' marketing to physicians shows that doctors are most influenced by brand preference and marketing that addresses the problems of drugs with many side effects, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS).
Peplin announces merger agreement with LEO Pharma
Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash. This represents a purchase price of US$16.99 per common share of Peplin stock or A$1.03 per Peplin CHESS Depositary Interest (CDI).
NicOx announces publication of blood pressure results from the phase 3 study of naproxcinod
NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).
› Verified 1 days ago